A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

This study tests a new mRNA-based drug called ABO2203 that directs the immune system's T cells to attack B-cell non-Hodgkin lymphoma (a type of blood cancer). It is a first-in-human trial evaluating safety and early effectiveness in patients whose cancer has returned or stopped responding to prior treatments. **You may be eligible if...** - You are 18 to 75 years old - You have relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) confirmed by biopsy - Your cancer is CD19-positive (a protein on the cancer cells) - You have at least one measurable tumor - You are in good overall health and your life expectancy is 3 months or more **You may NOT be eligible if...** - You have never received prior treatment for your lymphoma - Your cancer is a T-cell lymphoma - You have serious organ problems or active infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.